The prophylaxis of opportunistic infections in HIV-infected adults

References

• Dubé MP, Sattler FR. Pneumocystis carinii pneumonia. In: Merigan TC, Bartlet JG, Bolognsesi D (Eds). Textbook of AIDS Medicine (2nd Edition). Baltimore: Williams & Wilkins, 1999: 191–215.
   Google Scholar
• Stansell JD et al. Predictor of Pneunocystis carinii pneumonia in HIV-infected persons. Pulmonary complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155(1): 60–6.
   Google Scholar
• Waverling GJ et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet 1999; 353: 1293–8.
   Google Scholar
• Lopez Bernaldo de Quiros JC et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. N Eng J Med 2001; 344(3): 159–67.
   Google Scholar
• Lederberger B, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. N Eng J Med 2001; 344(3): 168–74.
   Google Scholar
• Furrer H, et al. Stopping primary prophylaxis in HIV-1 infected patients at high risk of toxoplasma encephalitis. Lancet 2000: 355: 2217–8.
   Google Scholar
• Clinical Guideline. The prevention and treatment of opportunistic infections in HIV-infected adults. Southern African Journal of HIV Medicine 2002; 1: 17–20.
   Google Scholar
• Southern African HIV Clinicians Society Guidelines for Tuberculosis Preventive Therapy in HIV infection. SAMJ 2000; 90: 59–4.
   Google Scholar
• Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000; 49:RR6.
   Google Scholar
• Perneger TV, et al. Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years. BMJ 1995; 311: 1468–71.
   Google Scholar
• WHO Global Tuberculosis Programme/UNAIDS. Preventive therapy in persons living with HIV. Wkly Epidemiol Rec 1999; 74: 385–398.
   Google Scholar
• Mwinga A, et al. Twice weekly Tuberculosis Preventive Therapy in HIV Infection in Zambia. AIDS 1998; 12: 2447–57.
   Google Scholar
• Wadhawan D, et al. Preventive Tuberculosis Chemotherapy with Isonaizid among Patients infected with HIV-1. 9^th International Conference on AIDS, Berlin, 1993.
   Google Scholar
• Mussini C, Pezzotti P, Miró JM. Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study. Clin Infect Dis. 2004; 38(4): 565–71.
   Google Scholar
• Cohen JP, Mcauley C. Susceptibility to influenza-A in HIV-positive patients. JAMA 1989; 261: 245
   Google Scholar
• Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection.
   Google Scholar
• Centers for Disease Control and Prevention. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000; 49: 1–38.
   Google Scholar
• Kroon FP, et al. Antibody response to influenza, tetanus and pneumococal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 1994; 8: 469–76.
   Google Scholar
• O'Brien WA, et al. Human immunodeficiency virus type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995; 86: 1082–9.
   Google Scholar
• Pekka Nuoriti J, et al. Epidemiologic relation between HIV and Invasive Pneumococcal Disease in San Francisco County, California. Ann Int Med 2000; 132: 182–90.
   Google Scholar
• Jefferson T, Demicheli, V. Polysaccharide pneumococcal vaccines. BMJ 2002; 325: 292–3.
   Google Scholar
• French N, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355: 2106.
   Google Scholar
• The 2002 UPSHDS/IDSA Guidelines for the Prevention of opportunistic Infections in Persons with Human Immunodeficiency Virus. MMWR 2002; 51 [RR-8:1].
   Google Scholar
• Currier JS, Williams PL, Koletar SL, et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+cell count. Ann Intern Med 2000; 133: 493–503.
   Google Scholar
• El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. N Engl J Med 2000; 342: 1085–92.
   Google Scholar
• Aberg JA, Yajko DM and Jacobson MA. Eradication of AIDS-related disseminated Mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. J Infect Dis 1998; 178: 1446–9.
   Google Scholar